Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.

Cancer gene therapy - 1 Jul 2002

Buller Richard E, Runnebaum Ingo B, Karlan Beth Y, Horowitz Jo Ann, Shahin Mark, Buekers Thomas, Petrauskas Stan, Kreienberg Rolf, Slamon Dennis, Pegram Mark

Abstract excerpt

PURPOSE: To determine the safety, gene transfer, host immune response, and pharmacokinetics of a replication-deficient adenovirus encoding human, recombinant, wild-type p53 (SCH 58500) delivered into the peritoneal cavity (i.p.) alone and sequentially in combination with platinum-based chemotherapy, of patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer containing aberrant or mutant p53....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CA-125 Antigen

Share to Carboplatin

Share to Combined Modality Therapy

Share to Fallopian Tube Neoplasms

Share to Paclitaxel

Share to Peritoneal Neoplasms

Source

Identifiers

PMID: 12082455
DOI: 10.1038/sj.cgt.7700472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.PMID 12082455Read ↗

Adenoviral-Mediated Suicide Gene Therapy for Ovarian CancerSemantic proximity Read ↗

Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerSemantic proximity Read ↗

Adenovirus-based p53 gene therapy in ovarian cancer.Semantic proximity Read ↗

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectivesSemantic proximity Read ↗

Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.Semantic proximity Read ↗

From gene therapy to virotherapy for ovarian cancer.Semantic proximity Read ↗

Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.Semantic proximity Read ↗

A Phase I Study of Adenovirus-Mediated Wild-Type <i>p53</i> Gene Transfer in Patients with Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.Semantic proximity Read ↗

Alteration of a p53 gene status affects outcome of patients with recurrent ovarian cancer.Semantic proximity Read ↗

Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy.Semantic proximity Read ↗

Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.